Final overall survival analysis and organ-specific target lesion assessments with two-year follow-up in CheckMate 9ER: Nivolumab plus cabozantinib versus sunitinib for patients with advanced renal cell carcinoma.

被引：18
|
作者：
Powles, Thomas
Choueiri, Toni K.
Burotto, Mauricio
Escudier, Bernard
Bourlon, Maria Teresa
Shah, Amishi Yogesh
Suarez, Cristina
Hamzaj, Alketa
Porta, Camillo
Hocking, Christopher
Kessler, Elizabeth R.
Gurney, Howard
Tomita, Yoshihiko
Bedke, Jens
Zhang, Joshua
Simsek, Burcin
Scheffold, Christian
Apolo, Andrea B.
Motzer, Robert J.
机构：
[1] Queen Mary Univ London, Canc Res UK Expt Canc Med Ctr, Barts Canc Inst, London, England
[2] Brigham & Womens Hosp, Dana Farber Canc Inst, Lank Ctr Genitourinary Oncol, 75 Francis St, Boston, MA 02115 USA
[3] Harvard Med Sch, Boston, MA 02115 USA
[4] Bradford Hill Clin Res Ctr, Santiago, Chile
[5] Gustave Roussy, Villejuif, France
[6] Inst Nacl Ciencias Med & Nutr Salvador Zubiran, Urol Oncol Clin, Mexico City, DF, Mexico
[7] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[8] Vall dHebron Barcelona Hosp Campus, Hosp Univ Vall dHebron, Vall dHebron Inst Oncol VHIO, Barcelona, Spain
[9] Ist Toscano Tumori, Osped San Donato, Arezzo, Italy
[10] Univ Pavia, Pavia, Italy
[11] Lyell McEwin Hosp, Elizabeth Vale, SA, Australia
[12] Univ Colorado, Canc Ctr, Anschutz Med Campus, Aurora, CO USA
[13] Westmead Hosp, Sydney, NSW, Australia
[14] Macquarie Univ Hosp, Sydney, NSW, Australia
[15] Niigata Univ, Grad Sch Med & Dent Sci, Niigata, Japan
[16] Eberhand Karls Univ Tubingen, Tubingen, Germany
[17] Bristol Myers Squibb, Princeton, NJ USA
[18] Exelixis Inc, Alameda, CA USA
[19] NCI, NIH, Bethesda, MD 20892 USA
[20] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 06期
关键词：
D O I：
10.1200/JCO.2022.40.6_suppl.350
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
350
引用
收藏
页数：4
相关论文
共 47 条
  • [31] Treatment-free survival and partitioned survival analysis of patients with advanced renal cell carcinoma treated with nivolumab plus ipilimumab versus sunitinib: 5-year update of CheckMate 214
    Mantia, Charlene M.
    Jegede, Opeyemi A.
    Plimack, Elizabeth R.
    Powles, Thomas
    Motzer, Robert J.
    Tannir, Nizar M.
    Lee, Chung-Han
    Tomita, Yoshihiko
    Voss, Martin H.
    Choueiri, Toni K.
    Rini, Brian, I
    Hammers, Hans J.
    Escudier, Bernard
    Albiges, Laurence
    Rosenblatt, Lisa
    Atkins, Michael B.
    Regan, Meredith M.
    McDermott, David F.
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2024, 12 (07) : 1 - 11
  • [32] Quality-adjusted time without symptoms of disease progression or toxicity (Q-TWiST) of nivolumab plus cabozantinib (N plus C) versus sunitinib (SUN) in treatment-naive, advanced/metastatic renal cell carcinoma (aRCC): A post-hoc analysis of CheckMate 9ER (CM 9ER) data.
    Cella, David
    Motzer, Robert J.
    May, Jessica
    Wallace, Joel
    Marteau, Florence
    Kwon, Youngmin
    Rusibamayila, Nifasha
    Botteman, Marc
    Ejzykowicz, Flavia
    Choueiri, Toni K.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [33] Final prespecified overall survival (OS) analysis of CLEAR: 4-year follow-up of lenvatinib plus pembrolizumab (L plus P) vs sunitinib (S) in patients (pts) with advanced renal cell carcinoma (aRCC)
    Motzer, Robert J.
    Porta, Camillo
    Eto, Masatoshi
    Powles, Thomas
    Gruenwald, Viktor
    Hutson, Thomas E.
    Alekseev, Boris
    Rha, Sun Young
    Merchan, Jaime R.
    Goh, Jeffrey C.
    Kapoor, Anil
    De Giorgi, Ugo
    Melichar, Bohuslav
    Hong, Sung-Hoo
    Gurney, Howard
    Rodriguez-Lopez, Karla
    He, Cixin S.
    Okpara, Chinyere
    McKenzie, Jodi
    Choueiri, Toni K.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [34] Final analysis of the CheckMate 025 trial comparing nivolumab (NIVO) versus everolimus (EVE) with >5 years of follow-up in patients with advanced renal cell carcinoma (aRCC)
    Motzer, Robert J.
    Tykodi, Scott S.
    Escudier, Bernard
    Oudard, Stephane
    Hammers, Hans J.
    McDermott, David F.
    George, Saby
    Castellano, Daniel
    Choueiri, Toni K.
    Alva, Ajjai Shivaram
    Richardet, Martin Eduardo
    Plimack, Elizabeth R.
    Srinivas, Sandy
    Procopio, Giuseppe
    Donskov, Frede
    Gurney, Howard
    Tomita, Yoshihiko
    McHenry, M. Brent
    Saggi, Shruti Shally
    Tannir, Nizar M.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
  • [35] Final prespecified overall survival (OS) analysis of the phase 3 CLEAR trial: 4-year follow-up of lenvatinib plus pembrolizumab (L plus P) vs sunitinib (S) in patients with advanced renal cell carcinoma (aRCC)
    Motzer, Robert J.
    Porta, Camillo
    Eto, Masatoshi
    Powles, Thomas
    Grunwald, Viktor
    Hutson, Thomas E.
    Alekseev, Boris
    Rha, Sun Young
    Merchan, Jamie R.
    Goh, Jeffrey C.
    De Giorgi, Ugo
    Melichar, Bohuslav
    Hong, Sung-Hoo
    Gurney, Howard
    Rodriguez-Lopez, Karla
    He, Cixin S.
    Okpara, Chinyere E.
    McKenzie, Jodi
    Choueiri, Toni K.
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2023, 19 : 72 - 73
  • [36] Nivolumab versus everolimus in advanced renal cell carcinoma: Japanese subgroup 3-year follow-up analysis from the Phase III CheckMate 025 study
    Tomita, Yoshihiko
    Fukasawa, Satoshi
    Shinohara, Nobuo
    Kitamura, Hiroshi
    Oya, Mototsugu
    Eto, Masatoshi
    Tanabe, Kazunari
    Saito, Mitsuru
    Kimura, Go
    Yonese, Junji
    Yao, Masahiro
    Uemura, Hirotsugu
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2019, 49 (06) : 506 - 514
  • [37] Nivolumab plus ipilimumab (N plus I) vs sunitinib (S) for first-line treatment of advanced renal cell carcinoma (aRCC) in CheckMate 214: 4-year follow-up and subgroup analysis of patients (pts) without nephrectomy
    Albiges, L.
    Tannir, N.
    Burotto, M.
    McDermott, D. F.
    Plimack, E. R.
    Barthelemy, P.
    Porta, C. G.
    Powles, T. B.
    Donskov, F.
    George, S.
    Kollmannsberger, C.
    Gurney, H.
    Grimm, M-O.
    Tomita, Y.
    Castellano Gauna, D.
    Rini, B. I.
    Choueiri, T. K.
    Saggi, S. S.
    McHenry, M. B.
    Motzer, R. J.
    ANNALS OF ONCOLOGY, 2020, 31 : S559 - S560
  • [38] Survival outcomes and independent response assessment with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma: 42-month follow-up of a randomized phase 3 clinical trial
    Motzer, Robert J.
    Escudier, Bernard
    McDermott, David F.
    Frontera, Osvaldo Aren
    Melichar, Bohuslav
    Powles, Thomas
    Donskov, Frede
    Plimack, Elizabeth R.
    Barthelemy, Philippe
    Hammers, Hans J.
    George, Saby
    Gruenwald, Viktor
    Porta, Camillo
    Neiman, Victoria
    Ravaud, Alain
    Choueiri, Toni K.
    Rini, Brian, I
    Salman, Pamela
    Kollmannsberger, Christian K.
    Tykodi, Scott S.
    Grimm, Marc-Oliver
    Gurney, Howard
    Leibowitz-Amit, Raya
    Geertsen, Poul F.
    Amin, Asim
    Tomita, Yoshihiko
    McHenry, M. Brent
    Saggi, Shruti Shally
    Tannir, Nizar M.
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 (02)
  • [39] Nivolumab plus ipilimumab vs sunitinib for first-line treatment of advanced renal cell carcinoma: 8-year follow-up with analyses in favorable risk patients from the phase 3 CheckMate 214 trial
    Atkins, Michael B.
    Escudier, Bernard
    Mcdermott, David F.
    Burotto, Mauricio
    Choueiri, Toni K.
    Hammers, Hans J.
    Plimack, Elizabeth R.
    Porta, Camillo
    George, Saby
    Powles, Thomas
    Donskov, Frede
    Kollmannsberger, Christian K.
    Grimm, Marc-Oliver
    Tomita, Yoshihiko
    Rini, Brian, I
    Jiang, Ruiyun
    Federov, Viktor
    Lee, Chung-Wei
    Desilva, Heshani
    Tannir, Nizar M.
    Motzer, Robert J.
    ONCOLOGIST, 2024, 29 : S17 - S18
  • [40] Nivolumab plus ipilimumab versus sunitinib for fi rst-line treatment of advanced renal cell carcinoma: extended 8-year follow-up results of efficacy and safety from the phase III CheckMate 214 trial
    Tannir, N. M.
    Albiges, L.
    Mcdermott, D. F.
    Burotto, M.
    Choueiri, T. K.
    Hammers, H. J.
    Barthelemy, P.
    Plimack, E. R.
    Portat, C.
    George, S.
    Donskov, F.
    Atkins, M. B.
    Gurney, H.
    Kollmannsberger, C. K.
    Grimm, M. -o.
    Barrios, C.
    Tomita, Y.
    Castellano, D.
    Gruenwald, V.
    Rini, B. I.
    Jiang, R.
    Desilva, H.
    Fedorov, V.
    Lee, C. -w.
    Motzer, R. J.
    ANNALS OF ONCOLOGY, 2024, 35 (11) : 1026 - 1038
12345